Historical valuation data is not available at this time.
PhoenixBio Co., Ltd. is a Japanese biotechnology company specializing in contract research and development services for the pharmaceutical industry. The company provides preclinical testing, toxicology studies, and efficacy evaluations for drug candidates, primarily serving biopharmaceutical clients. PhoenixBio operates a state-of-the-art laboratory facility in Japan and has established itself as a key player in the preclinical CRO (Contract Research Organization) market in Asia. The company's competitive advantage lies in its expertise in non-clinical studies, particularly in the fields of oncology and immunology, as well as its compliance with international regulatory standards (e.g., GLP).
Specialized capabilities in immuno-oncology and infectious disease models (per company website)
PhoenixBio operates in a growing preclinical CRO market with specialized capabilities, but faces competition from larger global players. Investment potential depends on the company's ability to maintain technical differentiation and expand its client base. Limited public financial disclosure increases uncertainty about profitability and growth trajectory.
Company website, industry reports on preclinical CRO market